Cardiomyopathy, Hypertrophic Obstructive Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06391788 -
Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Completed |
NCT02842242 -
A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
|
Phase 2 | |
Active, not recruiting |
NCT05414175 -
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
|
Phase 3 |